Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapy
The identification of germline BRCA1/BRCA2 pathogenic variants (PV) infer high remaining lifetime breast/ovarian cancer risks, but there is paucity of studies assessing breast cancer risk after ovarian cancer diagnosis. We reviewed the history of breast cancer in 895 PV heterozygotes (BRCA1 = 541)....
Gespeichert in:
| Veröffentlicht in: | Genetics in medicine 2024-09, Vol.26 (9), p.101172, Article 101172 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | 101172 |
| container_title | Genetics in medicine |
| container_volume | 26 |
| creator | Evans, D. Gareth Morgan, Robert D. Crosbie, Emma J. Howell, Sacha J. Forde, Claire Howell, Anthony Lalloo, Fiona Woodward, Emma R. |
| description | The identification of germline BRCA1/BRCA2 pathogenic variants (PV) infer high remaining lifetime breast/ovarian cancer risks, but there is paucity of studies assessing breast cancer risk after ovarian cancer diagnosis.
We reviewed the history of breast cancer in 895 PV heterozygotes (BRCA1 = 541). Cumulative annual breast cancer incidence was assessed at 2, 5, 10, and >10 years after ovarian cancer diagnosis date.
Breast cancer annual rates were evaluated in 701 assessable women with no breast cancer at ovarian diagnosis (BRCA1 = 425). Incidence was lower at 2 years (1.18%) and 2 to 5 years (1.13%) but rose thereafter for BRCA1 with incidence post 10 years in excess of 4% annually. Breast cancer pathology in BRCA1 PV heterozygotes showed less high-grade triple-negative breast cancer and more lower-grade hormone-receptor-positive cancer than women with no prior ovarian cancer. In the prospective cohort from ovarian cancer diagnosis, |
| doi_str_mv | 10.1016/j.gim.2024.101172 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3065979406</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1098360024001060</els_id><sourcerecordid>3065979406</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-9c98fdf3e085984a43938810ad58e9ea2814afa4270153f7b64a85b56b7d5e03</originalsourceid><addsrcrecordid>eNp9kEtv1DAUhS0Eog_4AWyQl2wyXMdOYsOqHUFBGqlS1b11J7mZ8WgSB9tTNOz6z_GQtks292Gdc6z7MfZBwEKAqD_vFhs3LEoo1WkXTfmKnYtKQgGyrl_nGYwuZA1wxi5i3AGIRpbwlp1JrVUjTHnOHq8DYUy8xbGlwLFPufoHDA7H50c38uu75ZXgOHb_ppJPmLZ-Q6Nr-axNfEvZ6v8cNz5R_MJX_ne2BswL733gFT8Shsgnf_ptS4NPWwo4Hd-xNz3uI71_6pfs_vu3--WPYnV783N5tSpaqXQqTGt03_WSQFdGK1TS5CsEYFdpMoSlFgp7VGUDGUHfrGuFulpX9brpKgJ5yT7NsVPwvw4Ukx1cbGm_x5H8IVoJdWUao6DOUjFL2-BjDNTbKbgBw9EKsCfwdmczeHsCb2fw2fPxKf6wHqh7cTyTzoKvs4DyjQ-Ogo2to8y3c4HaZDvv_hP_F7pKkzg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3065979406</pqid></control><display><type>article</type><title>Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapy</title><source>Alma/SFX Local Collection</source><creator>Evans, D. Gareth ; Morgan, Robert D. ; Crosbie, Emma J. ; Howell, Sacha J. ; Forde, Claire ; Howell, Anthony ; Lalloo, Fiona ; Woodward, Emma R.</creator><creatorcontrib>Evans, D. Gareth ; Morgan, Robert D. ; Crosbie, Emma J. ; Howell, Sacha J. ; Forde, Claire ; Howell, Anthony ; Lalloo, Fiona ; Woodward, Emma R.</creatorcontrib><description>The identification of germline BRCA1/BRCA2 pathogenic variants (PV) infer high remaining lifetime breast/ovarian cancer risks, but there is paucity of studies assessing breast cancer risk after ovarian cancer diagnosis.
We reviewed the history of breast cancer in 895 PV heterozygotes (BRCA1 = 541). Cumulative annual breast cancer incidence was assessed at 2, 5, 10, and >10 years after ovarian cancer diagnosis date.
Breast cancer annual rates were evaluated in 701 assessable women with no breast cancer at ovarian diagnosis (BRCA1 = 425). Incidence was lower at 2 years (1.18%) and 2 to 5 years (1.13%) but rose thereafter for BRCA1 with incidence post 10 years in excess of 4% annually. Breast cancer pathology in BRCA1 PV heterozygotes showed less high-grade triple-negative breast cancer and more lower-grade hormone-receptor-positive cancer than women with no prior ovarian cancer. In the prospective cohort from ovarian cancer diagnosis, <4% of all deaths were caused by breast cancer, although 50% of deaths in women with breast cancer after ovarian cancer diagnosis were due to breast cancer.
Women can be reassured that incidence of breast cancer after ovarian cancer diagnosis is relatively low. It appears likely that this effect is due to platinum-based chemotherapy. Nonetheless women need to be aware that incidence increases thereafter, especially after 10 years.</description><identifier>ISSN: 1098-3600</identifier><identifier>ISSN: 1530-0366</identifier><identifier>EISSN: 1530-0366</identifier><identifier>DOI: 10.1016/j.gim.2024.101172</identifier><identifier>PMID: 38847192</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>BRCA1 ; BRCA2 ; Breast cancer ; Ovarian cancer ; Survival</subject><ispartof>Genetics in medicine, 2024-09, Vol.26 (9), p.101172, Article 101172</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024. Published by Elsevier Inc.</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c348t-9c98fdf3e085984a43938810ad58e9ea2814afa4270153f7b64a85b56b7d5e03</cites><orcidid>0000-0002-8482-5784</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38847192$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Evans, D. Gareth</creatorcontrib><creatorcontrib>Morgan, Robert D.</creatorcontrib><creatorcontrib>Crosbie, Emma J.</creatorcontrib><creatorcontrib>Howell, Sacha J.</creatorcontrib><creatorcontrib>Forde, Claire</creatorcontrib><creatorcontrib>Howell, Anthony</creatorcontrib><creatorcontrib>Lalloo, Fiona</creatorcontrib><creatorcontrib>Woodward, Emma R.</creatorcontrib><title>Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapy</title><title>Genetics in medicine</title><addtitle>Genet Med</addtitle><description>The identification of germline BRCA1/BRCA2 pathogenic variants (PV) infer high remaining lifetime breast/ovarian cancer risks, but there is paucity of studies assessing breast cancer risk after ovarian cancer diagnosis.
We reviewed the history of breast cancer in 895 PV heterozygotes (BRCA1 = 541). Cumulative annual breast cancer incidence was assessed at 2, 5, 10, and >10 years after ovarian cancer diagnosis date.
Breast cancer annual rates were evaluated in 701 assessable women with no breast cancer at ovarian diagnosis (BRCA1 = 425). Incidence was lower at 2 years (1.18%) and 2 to 5 years (1.13%) but rose thereafter for BRCA1 with incidence post 10 years in excess of 4% annually. Breast cancer pathology in BRCA1 PV heterozygotes showed less high-grade triple-negative breast cancer and more lower-grade hormone-receptor-positive cancer than women with no prior ovarian cancer. In the prospective cohort from ovarian cancer diagnosis, <4% of all deaths were caused by breast cancer, although 50% of deaths in women with breast cancer after ovarian cancer diagnosis were due to breast cancer.
Women can be reassured that incidence of breast cancer after ovarian cancer diagnosis is relatively low. It appears likely that this effect is due to platinum-based chemotherapy. Nonetheless women need to be aware that incidence increases thereafter, especially after 10 years.</description><subject>BRCA1</subject><subject>BRCA2</subject><subject>Breast cancer</subject><subject>Ovarian cancer</subject><subject>Survival</subject><issn>1098-3600</issn><issn>1530-0366</issn><issn>1530-0366</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kEtv1DAUhS0Eog_4AWyQl2wyXMdOYsOqHUFBGqlS1b11J7mZ8WgSB9tTNOz6z_GQtks292Gdc6z7MfZBwEKAqD_vFhs3LEoo1WkXTfmKnYtKQgGyrl_nGYwuZA1wxi5i3AGIRpbwlp1JrVUjTHnOHq8DYUy8xbGlwLFPufoHDA7H50c38uu75ZXgOHb_ppJPmLZ-Q6Nr-axNfEvZ6v8cNz5R_MJX_ne2BswL733gFT8Shsgnf_ptS4NPWwo4Hd-xNz3uI71_6pfs_vu3--WPYnV783N5tSpaqXQqTGt03_WSQFdGK1TS5CsEYFdpMoSlFgp7VGUDGUHfrGuFulpX9brpKgJ5yT7NsVPwvw4Ukx1cbGm_x5H8IVoJdWUao6DOUjFL2-BjDNTbKbgBw9EKsCfwdmczeHsCb2fw2fPxKf6wHqh7cTyTzoKvs4DyjQ-Ogo2to8y3c4HaZDvv_hP_F7pKkzg</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Evans, D. Gareth</creator><creator>Morgan, Robert D.</creator><creator>Crosbie, Emma J.</creator><creator>Howell, Sacha J.</creator><creator>Forde, Claire</creator><creator>Howell, Anthony</creator><creator>Lalloo, Fiona</creator><creator>Woodward, Emma R.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8482-5784</orcidid></search><sort><creationdate>20240901</creationdate><title>Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapy</title><author>Evans, D. Gareth ; Morgan, Robert D. ; Crosbie, Emma J. ; Howell, Sacha J. ; Forde, Claire ; Howell, Anthony ; Lalloo, Fiona ; Woodward, Emma R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-9c98fdf3e085984a43938810ad58e9ea2814afa4270153f7b64a85b56b7d5e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>BRCA1</topic><topic>BRCA2</topic><topic>Breast cancer</topic><topic>Ovarian cancer</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Evans, D. Gareth</creatorcontrib><creatorcontrib>Morgan, Robert D.</creatorcontrib><creatorcontrib>Crosbie, Emma J.</creatorcontrib><creatorcontrib>Howell, Sacha J.</creatorcontrib><creatorcontrib>Forde, Claire</creatorcontrib><creatorcontrib>Howell, Anthony</creatorcontrib><creatorcontrib>Lalloo, Fiona</creatorcontrib><creatorcontrib>Woodward, Emma R.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Genetics in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Evans, D. Gareth</au><au>Morgan, Robert D.</au><au>Crosbie, Emma J.</au><au>Howell, Sacha J.</au><au>Forde, Claire</au><au>Howell, Anthony</au><au>Lalloo, Fiona</au><au>Woodward, Emma R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapy</atitle><jtitle>Genetics in medicine</jtitle><addtitle>Genet Med</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>26</volume><issue>9</issue><spage>101172</spage><pages>101172-</pages><artnum>101172</artnum><issn>1098-3600</issn><issn>1530-0366</issn><eissn>1530-0366</eissn><abstract>The identification of germline BRCA1/BRCA2 pathogenic variants (PV) infer high remaining lifetime breast/ovarian cancer risks, but there is paucity of studies assessing breast cancer risk after ovarian cancer diagnosis.
We reviewed the history of breast cancer in 895 PV heterozygotes (BRCA1 = 541). Cumulative annual breast cancer incidence was assessed at 2, 5, 10, and >10 years after ovarian cancer diagnosis date.
Breast cancer annual rates were evaluated in 701 assessable women with no breast cancer at ovarian diagnosis (BRCA1 = 425). Incidence was lower at 2 years (1.18%) and 2 to 5 years (1.13%) but rose thereafter for BRCA1 with incidence post 10 years in excess of 4% annually. Breast cancer pathology in BRCA1 PV heterozygotes showed less high-grade triple-negative breast cancer and more lower-grade hormone-receptor-positive cancer than women with no prior ovarian cancer. In the prospective cohort from ovarian cancer diagnosis, <4% of all deaths were caused by breast cancer, although 50% of deaths in women with breast cancer after ovarian cancer diagnosis were due to breast cancer.
Women can be reassured that incidence of breast cancer after ovarian cancer diagnosis is relatively low. It appears likely that this effect is due to platinum-based chemotherapy. Nonetheless women need to be aware that incidence increases thereafter, especially after 10 years.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38847192</pmid><doi>10.1016/j.gim.2024.101172</doi><orcidid>https://orcid.org/0000-0002-8482-5784</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1098-3600 |
| ispartof | Genetics in medicine, 2024-09, Vol.26 (9), p.101172, Article 101172 |
| issn | 1098-3600 1530-0366 1530-0366 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3065979406 |
| source | Alma/SFX Local Collection |
| subjects | BRCA1 BRCA2 Breast cancer Ovarian cancer Survival |
| title | Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T07%3A17%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Breast%20cancer%20after%20ovarian%20cancer%20in%20BRCA1%20and%20BRCA2%20pathogenic%20variant%20heterozygotes:%20Lower%20rates%20for%205%20years%20post%20chemotherapy&rft.jtitle=Genetics%20in%20medicine&rft.au=Evans,%20D.%20Gareth&rft.date=2024-09-01&rft.volume=26&rft.issue=9&rft.spage=101172&rft.pages=101172-&rft.artnum=101172&rft.issn=1098-3600&rft.eissn=1530-0366&rft_id=info:doi/10.1016/j.gim.2024.101172&rft_dat=%3Cproquest_cross%3E3065979406%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3065979406&rft_id=info:pmid/38847192&rft_els_id=S1098360024001060&rfr_iscdi=true |